Relugolix

China [CN]

I. Basic Information

Project | Details

English Name | Relugolix

Chinese Name | Ruilugolix

CAS Number | 737789-87-6 NCBI

Chemical Name | N-(4-{1-[(2,6-Difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl}phenyl)-N'-methoxyurea

Molecular Formula | C₂₉H₂₇F₂N₇O₅S

Molecular Weight | 623.63 (free base)

Target | Pituitary GnRH receptor (IC₅₀=0.12 nM, highly selective)

Developer | Takeda Pharmaceutical (TAK-385)

Market Launch | December 2020 (USA, Orgovyx); July 2021 (EU, combination drug Ryeqo)

Dosage Form and Specifications | Film-coated tablets: 120mg (prostate cancer); Combination tablets: 40mg Relugolix + 1mg Estradiol + 0.5mg Norethindrone acetate (uterine fibroids/endometriosis) PMC

II. Physicochemical Properties

Parameter | Data

Appearance | White to off-white or slightly yellow solid

Solubility | Water (25℃): 0.04 mg/mL (slightly soluble); readily soluble in dimethyl sulfoxide (DMSO), methanol, soluble in ethanol, sparingly soluble in n-hexane

Dissociation Constant (pKa) | 9.1 (dimethylamino), 7.2 (urea group) (predicted value)

Melting Point | 198-202℃ (decomposition)

Stability | Stable for 36 months at 25℃/60% RH, store in a sealed, cool, and dry place, avoid high temperature, light, and moisture; stable under acidic conditions, easily degraded under alkaline conditions

Chiral Characteristics | Contains 3 chiral centers One chiral center, a single configurational isomer, optical purity > 99.5%

Partition coefficient (logP): 4.2 (predicted value)